Phase 2a, open-label, dose-escalating, multi-center pharmacokinetic study of favipiravir (T-705) in combination with oseltamivir in patients with severe influenza.
Wang Y, Zhong W, Salam A, Tarning J, Zhan Q, Huang JA, Weng H, Bai C, Ren Y, Yamada K, Wang D, Guo Q, Fang Q, Tsutomu S, Zou X, Li H, Gillesen A, Castle L, Chen C, Li H, Zhen J, Lu B, Duan J, Guo L, Jiang J, Cao R, Fan G, Li J, Hayden FG, Wang C, Horby P, Cao B.
Wang Y, et al. Among authors: li j, li h.
EBioMedicine. 2020 Dec;62:103125. doi: 10.1016/j.ebiom.2020.103125. Epub 2020 Nov 22.
EBioMedicine. 2020.
PMID: 33232871
Free PMC article.
Clinical Trial.